All type of patients: 2 trials - Göbel (Dutch study) - DRS
| diltiazem vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Acute (short term) treatment: 3 trials - Gibson - Machecourt - Zannad
| diltiazem vs | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| reinfarction | no data | | confirmed myocardial infarction | 0.97 [0.20 4.68] | p=1.00 | 0 | 75 | 1 | Machecourt, | | cardiac death | no data | | All cause death | 0.49 [0.08 2.84] | p=1.00 | 0 | 75 | 1 | Machecourt, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| diltiazem vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| reinfarction | no data | | confirmed myocardial infarction | NaN [NaN NaN] | p=1.00 | 0 | 34 | 1 | Zannad, | | cardiac death | no data | | All cause death | 1.21 [0.51 2.84] | p=1.00 | 0 | 610 | 2 | Gibson,Zannad, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Acute short term and post MI studies: 4 trials - Gibson - Machecourt - MDPIT - Zannad
| diltiazem vs | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| reinfarction | no data | | confirmed myocardial infarction | 0.97 [0.20 4.68] | p=1.00 | 0 | 75 | 1 | Machecourt, | | cardiac death | no data | | All cause death | 0.49 [0.08 2.84] | p=1.00 | 0 | 75 | 1 | Machecourt, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| diltiazem vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| reinfarction | 0.85 [0.65 1.13] | p=1.00 | 0 | 2466 | 1 | MDPIT, | | confirmed myocardial infarction | NaN [NaN NaN] | p=1.00 | 0 | 34 | 1 | Zannad, | | cardiac death | 1.03 [0.79 1.33] | p=1.00 | 0 | 2466 | 1 | MDPIT, | | All cause death | 1.01 [0.81 1.26] | p=1.00 | 0 | 3076 | 3 | Gibson,MDPIT,Zannad, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Long term studies: 1 trials - MDPIT
| diltiazem vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| reinfarction | 0.85 [0.65 1.13] | p=1.00 | 0 | 2466 | 1 | MDPIT, | | confirmed myocardial infarction | no data | | cardiac death | 1.03 [0.79 1.33] | p=1.00 | 0 | 2466 | 1 | MDPIT, | | All cause death | 1.00 [0.79 1.25] | p=1.00 | 0 | 2466 | 1 | MDPIT, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All type of patients: 2 trials - Liao - DiDi
| Diltiazem vs placebo | No demonstrated result suggested hospitalisation for heart failure by 74% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | Coronary death | no data | | hospitalisation for heart failure | 0.26 [0.13 0.52] | p=0.04 | 0 | 221 | 1 | Liao , | | All cause death | 0.59 [0.27 1.30] | p=1.00 | 0 | 407 | 2 | Liao ,DiDi, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All type of patient: 1 trials - NORDIL
| diltiazem vs diuretic or beta-blocker | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 1.04 [0.91 1.19] | p=1.00 | 0 | 10881 | 1 | NORDIL, | | Cardiovascular death | 1.15 [0.89 1.48] | p=1.00 | 0 | 10881 | 1 | NORDIL, | | stroke (fatal and non fatal) | 0.82 [0.66 1.01] | p=1.00 | 0 | 10881 | 1 | NORDIL, | | Coronary event | 1.14 [0.94 1.38] | p=1.00 | 0 | 10881 | 1 | NORDIL, | | Fatal MI | 1.13 [0.66 1.94] | p=1.00 | 0 | 10881 | 1 | NORDIL, | | Non fatal MI | 1.19 [0.94 1.50] | p=1.00 | 0 | 10881 | 1 | NORDIL, | | Heart failure | 1.18 [0.82 1.70] | p=1.00 | 0 | 10881 | 1 | NORDIL, | | Diabetes onset | 0.87 [0.72 1.05] | p=1.00 | 0 | 10881 | 1 | NORDIL, | | Angina | no data | | Peripheral arterial disease | no data | | End stage renal disease | no data | | Revascularization | no data | | All cause death | 1.02 [0.85 1.24] | p=1.00 | 0 | 10881 | 1 | NORDIL, | | Fatal stroke | 0.97 [0.53 1.76] | p=1.00 | 0 | 10881 | 1 | NORDIL, | | Non fatal stroke | 0.80 [0.64 1.01] | p=1.00 | 0 | 10881 | 1 | NORDIL, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Uncomplicated hypertension: 1 trials - NORDIL
| diltiazem vs diuretic or beta-blocker | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 1.04 [0.91 1.19] | p=1.00 | 0 | 10881 | 1 | NORDIL, | | Cardiovascular death | 1.15 [0.89 1.48] | p=1.00 | 0 | 10881 | 1 | NORDIL, | | stroke (fatal and non fatal) | 0.82 [0.66 1.01] | p=1.00 | 0 | 10881 | 1 | NORDIL, | | Coronary event | 1.14 [0.94 1.38] | p=1.00 | 0 | 10881 | 1 | NORDIL, | | Fatal MI | 1.13 [0.66 1.94] | p=1.00 | 0 | 10881 | 1 | NORDIL, | | Non fatal MI | 1.19 [0.94 1.50] | p=1.00 | 0 | 10881 | 1 | NORDIL, | | Heart failure | 1.18 [0.82 1.70] | p=1.00 | 0 | 10881 | 1 | NORDIL, | | Diabetes onset | 0.87 [0.72 1.05] | p=1.00 | 0 | 10881 | 1 | NORDIL, | | Angina | no data | | Peripheral arterial disease | no data | | End stage renal disease | no data | | Revascularization | no data | | All cause death | 1.02 [0.85 1.24] | p=1.00 | 0 | 10881 | 1 | NORDIL, | | Fatal stroke | 0.97 [0.53 1.76] | p=1.00 | 0 | 10881 | 1 | NORDIL, | | Non fatal stroke | 0.80 [0.64 1.01] | p=1.00 | 0 | 10881 | 1 | NORDIL, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All type of patients: 3 trials - Corcos - O’Keefe - Unverdorben
| diltiazem vs control | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| diltiazem vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All type of patients: 1 trials - MDPIT
| diltiazem vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| reinfarction | 0.85 [0.65 1.13] | p=1.00 | 0 | 2466 | 1 | MDPIT, | | confirmed myocardial infarction | no data | | cardiac death | 1.03 [0.79 1.33] | p=1.00 | 0 | 2466 | 1 | MDPIT, | | All cause death | 1.00 [0.79 1.25] | p=1.00 | 0 | 2466 | 1 | MDPIT, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
